U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C43H51N3O11
Molecular Weight 785.8785
Optical Activity UNSPECIFIED
Defined Stereocenters 9 / 9
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RIFAXIMIN

SMILES

CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C4=C(C(O)=C3C)C(O)=C(NC(=O)C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C5=C4N=C6C=C(C)C=CN56

InChI

InChIKey=NZCRJKRKKOLAOJ-XRCRFVBUSA-N
InChI=1S/C43H51N3O11/c1-19-14-16-46-28(18-19)44-32-29-30-37(50)25(7)40-31(29)41(52)43(9,57-40)55-17-15-27(54-10)22(4)39(56-26(8)47)24(6)36(49)23(5)35(48)20(2)12-11-13-21(3)42(53)45-33(34(32)46)38(30)51/h11-18,20,22-24,27,35-36,39,48-51H,1-10H3,(H,45,53)/b12-11+,17-15+,21-13-/t20-,22+,23+,24+,27-,35-,36+,39+,43-/m0/s1

HIDE SMILES / InChI

Molecular Formula C43H51N3O11
Molecular Weight 785.8785
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 9 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/cdi/rifaximin.html http://www.rxlist.com/xifaxan-drug.htm http://www.wikidoc.org/index.php/Special:Search?search=RIFAXIMIN

Rifaximin is a structural analog of rifampin and a non-systemic, gastrointestinal site-specific antibiotic. Rifaximin acts by inhibiting bacterial ribonucleic acid (RNA) synthesis and contributes to restore intestinal microflora imbalance. It is FDA approved for the treatment of travelers’ diarrhea, reduction in risk of overt hepatic encephalopathy (HE) recurrence and treatment of irritable bowel syndrome with diarrhea. More common side effects are: black, tarry stools; dizziness or lightheadedness; muscle spasm; rapid breathing; shortness of breath; trouble sleeping. Co-administration of cyclosporine, with XIFAXAN resulted in 83-fold and 124-fold increases in rifaximin mean Cmax in healthy subjects.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
25.0 µM [IC50]
Target ID: P0A8V2
Gene ID: 948488.0
Gene Symbol: rpoB
Target Organism: Escherichia coli (strain K12)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
XIFAXAN

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of XIFAXAN and other antibacterial drugs, XIFAXAN when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. XIFAXAN is a rifamycin antibacterial indicated for: The treatment of patients (≥ 12 years of age) with travelers’ diarrhea (TD) caused by noninvasive strains of ( ) Escherichia coli 1.1 Reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ≥ 18 years of age ( ) 1.2 Limitations of Use TD: Do not use in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than ( ) Escherichia coli 1.1 1.1 Travelers’ Diarrhea XIFAXAN 200 mg is indicated for the treatment of patients (≥ 12 years of age) with travelers’ diarrhea caused by noninvasive strains of Escherichia coli [see Warnings and Precautions ( ), Clinical Pharmacology ( ) and Clinical Studies ( )

Launch Date

2004
Preventing
XIFAXAN

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of XIFAXAN and other antibacterial drugs, XIFAXAN when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. XIFAXAN is a rifamycin antibacterial indicated for: The treatment of patients (≥ 12 years of age) with travelers’ diarrhea (TD) caused by noninvasive strains of ( ) Escherichia coli 1.1 Reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ≥ 18 years of age ( ) 1.2 Limitations of Use TD: Do not use in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than ( ) Escherichia coli 1.1 1.1 Travelers’ Diarrhea XIFAXAN 200 mg is indicated for the treatment of patients (≥ 12 years of age) with travelers’ diarrhea caused by noninvasive strains of Escherichia coli [see Warnings and Precautions ( ), Clinical Pharmacology ( ) and Clinical Studies ( )

Launch Date

2004
Primary
XIFAXAN

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of XIFAXAN and other antibacterial drugs, XIFAXAN when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. XIFAXAN is a rifamycin antibacterial indicated for: The treatment of patients (≥ 12 years of age) with travelers’ diarrhea (TD) caused by noninvasive strains of ( ) Escherichia coli 1.1 Reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ≥ 18 years of age ( ) 1.2 Limitations of Use TD: Do not use in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than ( ) Escherichia coli 1.1 1.1 Travelers’ Diarrhea XIFAXAN 200 mg is indicated for the treatment of patients (≥ 12 years of age) with travelers’ diarrhea caused by noninvasive strains of Escherichia coli [see Warnings and Precautions ( ), Clinical Pharmacology ( ) and Clinical Studies ( )

Launch Date

2004
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
4.1 ng/mL
550 mg single, oral
dose: 550 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIFAXIMIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
3.4 ng/mL
550 mg 2 times / day steady-state, oral
dose: 550 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RIFAXIMIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4.8 ng/mL
550 mg single, oral
dose: 550 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIFAXIMIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
11.1 ng × h/mL
550 mg single, oral
dose: 550 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIFAXIMIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
12.3 ng × h/mL
550 mg 2 times / day steady-state, oral
dose: 550 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
RIFAXIMIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
22.5 ng × h/mL
550 mg single, oral
dose: 550 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIFAXIMIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.8 h
550 mg single, oral
dose: 550 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIFAXIMIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
4.8 h
550 mg single, oral
dose: 550 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIFAXIMIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
32.5%
550 mg single, oral
dose: 550 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RIFAXIMIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
200 mg 3 times / day multiple, oral
Recommended
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources: Page: p.4
unhealthy, 18-79
n = 320
Health Status: unhealthy
Condition: Travelers’ diarrhea caused by noninvasive strains of Escherichia coli
Age Group: 18-79
Sex: M+F
Population Size: 320
Sources: Page: p.4
Disc. AE: Taste loss, Dysentery...
AEs leading to
discontinuation/dose reduction:
Taste loss
Dysentery
Weight decrease
Anorexia
Nausea
Nasal passage irritation
Sources: Page: p.4
1200 mg 2 times / day multiple, oral
Highest studied dose
Dose: 1200 mg, 2 times / day
Route: oral
Route: multiple
Dose: 1200 mg, 2 times / day
Sources: Page: p.478
unhealthy, 18–73
n = 99
Health Status: unhealthy
Condition: Crohn's disease
Age Group: 18–73
Sex: M+F
Population Size: 99
Sources: Page: p.478
800 mg 3 times / day multiple, oral
Highest studied dose
Dose: 800 mg, 3 times / day
Route: oral
Route: multiple
Dose: 800 mg, 3 times / day
Sources: Page: p.207
unhealthy, 32-82
n = 17
Health Status: unhealthy
Condition: Hepatic Encephalopathy
Age Group: 32-82
Sex: M+F
Population Size: 17
Sources: Page: p.207
550 mg 3 times / day multiple, oral
Studied dose
Dose: 550 mg, 3 times / day
Route: oral
Route: multiple
Dose: 550 mg, 3 times / day
Sources: Page: p.1119
unhealthy, 46.4
n = 2579
Health Status: unhealthy
Condition: Diarrhea-Predominant Irritable Bowel Syndrome
Age Group: 46.4
Sex: M+F
Population Size: 2579
Sources: Page: p.1119
AEs

AEs

AESignificanceDosePopulation
Anorexia Disc. AE
200 mg 3 times / day multiple, oral
Recommended
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources: Page: p.4
unhealthy, 18-79
n = 320
Health Status: unhealthy
Condition: Travelers’ diarrhea caused by noninvasive strains of Escherichia coli
Age Group: 18-79
Sex: M+F
Population Size: 320
Sources: Page: p.4
Dysentery Disc. AE
200 mg 3 times / day multiple, oral
Recommended
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources: Page: p.4
unhealthy, 18-79
n = 320
Health Status: unhealthy
Condition: Travelers’ diarrhea caused by noninvasive strains of Escherichia coli
Age Group: 18-79
Sex: M+F
Population Size: 320
Sources: Page: p.4
Nasal passage irritation Disc. AE
200 mg 3 times / day multiple, oral
Recommended
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources: Page: p.4
unhealthy, 18-79
n = 320
Health Status: unhealthy
Condition: Travelers’ diarrhea caused by noninvasive strains of Escherichia coli
Age Group: 18-79
Sex: M+F
Population Size: 320
Sources: Page: p.4
Nausea Disc. AE
200 mg 3 times / day multiple, oral
Recommended
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources: Page: p.4
unhealthy, 18-79
n = 320
Health Status: unhealthy
Condition: Travelers’ diarrhea caused by noninvasive strains of Escherichia coli
Age Group: 18-79
Sex: M+F
Population Size: 320
Sources: Page: p.4
Taste loss Disc. AE
200 mg 3 times / day multiple, oral
Recommended
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources: Page: p.4
unhealthy, 18-79
n = 320
Health Status: unhealthy
Condition: Travelers’ diarrhea caused by noninvasive strains of Escherichia coli
Age Group: 18-79
Sex: M+F
Population Size: 320
Sources: Page: p.4
Weight decrease Disc. AE
200 mg 3 times / day multiple, oral
Recommended
Dose: 200 mg, 3 times / day
Route: oral
Route: multiple
Dose: 200 mg, 3 times / day
Sources: Page: p.4
unhealthy, 18-79
n = 320
Health Status: unhealthy
Condition: Travelers’ diarrhea caused by noninvasive strains of Escherichia coli
Age Group: 18-79
Sex: M+F
Population Size: 320
Sources: Page: p.4
Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
likely
no
no
no
no
no
no
no
no
yes
weak (co-administration study)
Comment: Mean AUC of midazolam was 3.8% and 8.8% lower, respectively, after rifaximin was administered 3x a day for 7 days and 14 days, respectively.
Page: 30.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.
2001 Nov
Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety.
2005
Rifaximin pharmacology and clinical implications.
2009 Jun
Pharmacotherapy of hepatic encephalopathy in cirrhosis.
2010 Jun
Rifaximin in hepatic encephalopathy: more than just a non-absorbable antibiotic?
2010 Sep
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity.
2011 Jul 14
Patents

Sample Use Guides

Travelers’ Diarrhea: The recommended dose is one 200 mg tablet taken orally three times a day for 3 days. Hepatic Encephalopathy: The recommended dose is one 550 mg tablet taken orally two times a day. Irritable Bowel Syndrome with Diarrhea: The recommended dose is one 550 mg tablet taken orally three times a day for 14 days. It can be taken with or without food.
Route of Administration: Oral
The activities of rifaximin against enteropathogens were found to be as follows: a MIC50 of 4 to 8 μg/ml and a MIC90 of >8 μg/ml.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:44:56 GMT 2023
Edited
by admin
on Fri Dec 15 15:44:56 GMT 2023
Record UNII
L36O5T016N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RIFAXIMIN
EP   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
(2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-25-(ACETYLOXY)-5,6,21,23-TETRAHYDROXY-27-METHOXY-2,4,11,16,20,22,24,26-OCTAMETHYL-2,7-(EPOXYPENTADECA(1,11,13)TRIENIMINO)BENZOFURO(4,5-E)PYRIDO(1,2-A)BENZIMIDAZOLE-1,15(2H)-DIONE
Common Name English
RIFAXIMIN [USAN]
Common Name English
rifaximin [INN]
Common Name English
NSC-758957
Code English
RIFAXIMIN [VANDF]
Common Name English
RIFAXIMIN [EP IMPURITY]
Common Name English
RIFAXIMIN [ORANGE BOOK]
Common Name English
RIFAMYCIN L 105
Common Name English
RIFAXIDIN
Common Name English
L-105
Common Name English
RIFAXIMIN [EP MONOGRAPH]
Common Name English
Rifaximin [WHO-DD]
Common Name English
RIFAXIMIN [MART.]
Common Name English
RIFAXIMIN [MI]
Common Name English
XIFAXSAN
Brand Name English
2,7-(EPOXYPENTADECA(1,11,13)TRIENIMINO)BENZOFURO(4,5-E)PYRIDO(1,2-A)BENZIMIDAZOLE-1,15(2H)-DIONE, 25-(ACETYLOXY)-5,6,21,23-TETRAHYDROXY-27-METHOXY-2,4,11,16,20,22,24,26-OCTAMETHYL-, (2S,16Z,18E,20S,21S,22R,23R,24R,25S,26R,27S,28E)-
Systematic Name English
RIFAXIMIN [JAN]
Common Name English
4-DEOXY-4'-METHYLPYRIDO(1',2'-1,2)IMIDAZO(5,4-C)RIFAMYCIN SV
Common Name English
Classification Tree Code System Code
WHO-ATC D06AX11
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
NDF-RT N0000007911
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
NDF-RT N0000007911
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
WHO-VATC QD06AX11
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
FDA ORPHAN DRUG 778520
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
NDF-RT N0000007911
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
WHO-VATC QA07AA11
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
NCI_THESAURUS C258
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
FDA ORPHAN DRUG 109497
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
WHO-VATC QJ51XX01
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
WHO-VATC QG51AA06
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
NDF-RT N0000175500
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
WHO-ATC A07AA11
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
NDF-RT N0000007911
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
LIVERTOX NBK548082
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
Code System Code Type Description
SMS_ID
100000091946
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
PRIMARY
INN
5244
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
PRIMARY
RXCUI
35619
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
PRIMARY RxNorm
CAS
80621-81-4
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
PRIMARY
LACTMED
Rifaximin
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
PRIMARY
EVMPD
SUB10312MIG
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
PRIMARY
FDA UNII
L36O5T016N
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
PRIMARY
DAILYMED
L36O5T016N
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
PRIMARY
MERCK INDEX
m9615
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
PRIMARY Merck Index
ChEMBL
CHEMBL1617
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
PRIMARY
CHEBI
75246
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
PRIMARY
USAN
EE-33
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
PRIMARY
NCI_THESAURUS
C61926
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
PRIMARY
NSC
758957
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
PRIMARY
DRUG CENTRAL
2379
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
PRIMARY
EPA CompTox
DTXSID7045998
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
PRIMARY
DRUG BANK
DB01220
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
PRIMARY
MESH
C042734
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
PRIMARY
PUBCHEM
6436173
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
PRIMARY
WIKIPEDIA
RIFAXIMIN
Created by admin on Fri Dec 15 15:44:56 GMT 2023 , Edited by admin on Fri Dec 15 15:44:56 GMT 2023
PRIMARY
Related Record Type Details
BINDER->LIGAND
BINDING
BINDER->LIGAND
BINDING
METABOLIC ENZYME -> INDUCER
EXCRETED UNCHANGED
After oral administration of 400 mg 14C-rifaximin to healthy volunteers, approximately 97% of the dose was recovered in feces, almost entirely as unchanged drug, and 0.32% was recovered in the urine.
FECAL
METABOLIC ENZYME -> SUBSTRATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC POPULATION: HEALTHY SUBJECTS

Biological Half-life PHARMACOKINETIC POPULATION: ISB-D PATIENTS

Tmax PHARMACOKINETIC POPULATION: HEALTHY SUBJECTS AND ISB-D PATIENTS